Cover Image

Preclinical efficacy of tasquinimod in myelodysplastic neoplasms: Restoring erythropoiesis and mitigating bone loss

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Manja Wobus, Heike Weidner, Rebekka Wehner, Anna‐Lena Baumann, Kristin Möbus, Ekaterina Balaian, Marie Törngren, Erik Vahtola, Helena Eriksson, Susann Winter, Uwe Platzbecker, Triantafyllos Chavakis, Lorenz Christian Hofbauer, Martina Rauner, Martin Bornhäuser, Katja Sockel
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	HemaSphere
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Luspatercept: A peaceful revolution in the standard of care for myelodysplastic neoplasms
by: Francesca Vinchi, et al.
Published: (2024)

Prognostic value of flow cytometry in myelodysplastic neoplasms (MDS): Composition of a FCM‐prognostic score (FCM‐PS) for overall survival
by: Aida Santaolalla, et al.
Published: (2026)

Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium
by: Cristina A. Tentori, et al.
Published: (2024)

“Low‐risk” myelodysplastic neoplasm (MDS): Time for a name change?
by: Shoshana Burke, et al.
Published: (2025)

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
by: Fabio Efficace, et al.
Published: (2024)

Erythropoiesis in health and disease: Distinguishing defective and ineffective erythropoiesis
by: Sara El Hoss, et al.
Published: (2026)

News on sickle cell disease: Heme‐driven disordered erythropoiesis
by: Francesca Vinchi
Published: (2024)

MMS22L is a novel key actor of normal and pathological erythropoiesis
by: Elia Colin, et al.
Published: (2025)

Independent confirmation of the immunophenotypic ELN Scoring System in patients with MDS and CMML
by: Uta Oelschlaegel, et al.
Published: (2025)

Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies
by: Uwe Platzbecker, et al.
Published: (2025)

Mitochondrial retention in mature red blood cells from patients with sickle cell disease is associated with stress erythropoiesis but not with proinflammatory state
by: Marc Romana, et al.
Published: (2024)

Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?
by: Baptiste Le Calvez, et al.
Published: (2024)

Are we ready for disease modification in myeloproliferative neoplasms?
by: Claire N. Harrison
Published: (2024)

Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes
by: Enrico Attardi, et al.
Published: (2024)

Treatment patterns and outcomes with luspatercept in patients with lower‐risk myelodysplastic syndromes: A retrospective US cohort analysis
by: Sudipto Mukherjee, et al.
Published: (2024)

Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower‐risk myelodysplastic syndromes
by: David Rombaut, et al.
Published: (2025)

Age‐stratified machine learning identifies divergent prognostic significance of molecular alterations in AML
by: Jan‐Niklas Eckardt, et al.
Published: (2025)

Inflammatory disorders in IDH‐mutated myeloid neoplasms: Characteristics and response to IDH inhibitors
by: Romain Stammler, et al.
Published: (2025)

Unraveling the role of TP53 mutations in myeloproliferative neoplasms: Molecular mechanisms of leukemic transformation
by: Suzana da Silva‐Benedito, et al.
Published: (2026)

Preclinical evaluation of the CD38‐targeting engineered toxin body MT‐0169 against multiple myeloma
by: Wassilis S. C. Bruins, et al.
Published: (2024)

Mortality in patients with lymphoid malignancies and multiple myeloma was stable upon and during the COVID‐19 pandemic: A population‐based, nation‐wide study
by: Tereza Faitová, et al.
Published: (2024)

A single JAK2 ‐V617F hematopoietic stem cell can initiate myeloproliferative neoplasm when transplanted into non‐conditioned recipient mice
by: Quentin Kimmerlin, et al.
Published: (2026)

A novel MYB::PAIP1 oncogenic fusion in pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN) is dependent on BCL2 expression and is sensitive to venetoclax
by: Hansen J. Kosasih, et al.
Published: (2024)

Mitigation of atrial fibrillation‐related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG‐MPN bioregistry
by: Hyunyee Rosa Cho, et al.
Published: (2025)

Comparative analysis of macrophage feeder systems reveals distinct behaviors and key transcriptional shifts in chronic lymphocytic leukemia cells via coculture
by: Viktoria Kohlhas, et al.
Published: (2025)

Clonal hematopoiesis in AML long‐term survivors: Risk factors and clinical consequences
by: Simon M. Krauß, et al.
Published: (2025)

Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma
by: Patrick Born, et al.
Published: (2025)

A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mut AML in MRD neg remission after intensive induction
by: Konstanze Döhner, et al.
Published: (2025)

Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single‐cell profiling in anti‐BCMA CAR T‐treated myeloma
by: Thomas C. Wiemers, et al.
Published: (2026)

Inhibiting the alarmin‐driven hematopoiesis‐stromal cell crosstalk in primary myelofibrosis ameliorates bone marrow fibrosis
by: Hélène F. E. Gleitz, et al.
Published: (2025)

Intra‐subtype heterogeneity shapes treatment response in KMT2A ‐rearranged ALL across all age groups
by: Alina M. Hartmann, et al.
Published: (2026)

Issue Information
Published: (2025)

Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia
by: Raúl Córdoba, et al.
Published: (2026)

Efficacy and safety of CAR T‐cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition
by: Anna Ossami Saidy, et al.
Published: (2025)

Cell‐free DNA for detection and monitoring of extramedullary AML relapse
by: Henri C. Hupe, et al.
Published: (2025)

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML
by: David A. Sallman, et al.
Published: (2025)

TET3 regulates hematopoietic stem cell homeostasis during embryonic and adult hematopoiesis
by: Harmony C. Ketchum, et al.
Published: (2025)

Dynamics of BCR::ABL1 transcript levels and clinical outcomes after switch to second‐line therapy in pediatric chronic myeloid leukemia
by: Stephanie Sembill, et al.
Published: (2026)

HELIOS Action: Advancing research, education, and equity in hemoglobinopathies across Europe and beyond
by: Sotiroula Chatzimatthaiou, et al.
Published: (2025)

Correction to “Quality of vitamin K antagonist treatment during the last year of life”
Published: (2025)